02 Jul 2026 Recon: FDA approves Vertex gene therapy for children with sickle cell disease; Judge blocks Colorado price cap on Amgen’s Enbrel Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
30 Jun 2026 Recon: FDA rejects Unicycive's kidney disease therapy; Top FDA gene therapy regulator to step down Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
29 Jun 2026 Recon: FDA will review generic GLP-1; India floats faster licensing for some devices Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
26 Jun 2026 WHO issues guideline to curb environmental waste in pharmaceutical manufacturing The World Health Organization (WHO) published a draft guidance this month that aims to assist regulators and pharmaceutical companies in integrating environmental sustainability strategies and metrics into pharmaceutical manufacturing. Regulatory News
25 Jun 2026 Recon: FDA grants breakthrough designation to gen AI radiology tools; Oncology paper retraction casts doubt on China research Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
18 Jun 2026 Recon: Biogen to acquire RayThera for $1B; FDA approves first generic version Roche flu drug Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
16 Jun 2026 Recon: FDA approves Merck's Welireg-Keytruda combo for kidney cancer; FDA staff signal support for Moderna’s flu shot in older adults Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
15 Jun 2026 Recon: Neumora abandons depression drug after Phase 3 misses; FDA signs off on Colorado’s plan to import drugs from Canada Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
11 Jun 2026 Recon: MHRA approves Novo’s weight-loss pill; Some US employers look to cut GLP-1 coverage in 2027 Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
09 Jun 2026 Recon: GSK to buy Nuvalent for $10.6B; Pentagon labels WuXi AppTec as linked to Chinese military Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
